Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ODTX with free AI briefings, catalyst countdowns, and dilution alerts.

ODTX · Odyssey Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$387M Cash on Hand
30.5mo Cash Runway
8% Short Interest
$34.67 Analyst Target (6)
Follow ODTX by email Get an email when ODTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ODTX, unsubscribe in one click. Privacy

📣 What ODTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
OD-07656 Ulcerative Colitis (UC) Phase 2 · NCT06850727 Recruiting
[14C]OD-001 Health Volunteers Phase 1 · NCT07900607 Recruiting
PRV-002 Traumatic Brain Injury (TBI) Phase 1 · NCT05033444 Completed

Also used in these trials (approved or third-party drugs, not ODTX's own candidates): Vedolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ODTX holds $387M in cash and short-term investments (as of Sep 30, 2026) and burns about $38M/quarter from operations, an estimated runway of 30.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ODTX files for a raise →

👥 Who Owns ODTX

Insiders 24.8% Other 5%+ holders 15.2% Institutions (94 holders) 60% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 6,239,237 12.98% 2026-09-30
SR ONE CAPITAL MANAGEMENT, LLC
10% owner
Insider 3,794,883 7.89% 2026-05-11
TPG GP A, LLC
Former 10% Owner
Insider 3,690,146 7.68% 2026-05-11
Jeito II S.L.P. 5%+ holder (13D) 3,690,145 7.68% 2026-05-08
Lightspeed Venture Partners XV-B (Ignite 5%+ holder (13G) 3,608,443 7.51% 2026-05-11
Lightspeed Management Company, L.L.C. Institution (13F) 3,608,443 7.51% 2026-09-30
Nan (LN) Li
Director
Insider 3,333,516 6.94% 2026-05-11
Dimension Capital II, L.P.
Director
Includes shares also reported by Nan (LN) Li, counted once
Insider 3,333,516 6.94% 2026-05-08
Dimension Management, L.P. Institution (13G, 5%+) 3,333,516 6.94% 2026-05-08
Orbimed Advisors LLC. Institution (13F) 3,001,198 6.24% 2026-09-30
Sanofi Institution (13F) 1,990,200 4.14% 2026-09-30
MPM Bioimpact LLC Institution (13F) 1,289,091 2.68% 2026-09-30

Share count 48,067,877 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ODTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ODTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.